Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LP-184 |
| Synonyms | |
| Therapy Description |
LP-184 is a prodrug that is converted to an alkylating agent by PTGR1, which potentially inhibits tumor growth (PMID: 37494541). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LP-184 | LP184|LP 184 | LP-184 is a prodrug that is converted to an alkylating agent by PTGR1, which potentially inhibits tumor growth (PMID: 37494541). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05933265 | Phase I | LP-184 | Study of LP-184 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |